CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.39: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.08BCNY608.85M · vs all stocks (USD)
Revenue (TTM)
429.09MCNY64.08M · vs all stocks (USD)
Profit Margin
-66.22%Beta
0.5820xvs all stocks
52-Week Change
68.43%vs all stocks
Market Capitalization
4.08BCNY608.85M · vs all stocks (USD)
Enterprise Value
4.50BCNY672.32M · vs all stocks (USD)
Price to Sales (TTM)
9.41xPrice to Book (MRQ)
7.28xEnterprise to Revenue
10.49xEnterprise to EBITDA
-82.91xGross Margin
36.77%Profit Margin
-66.22%Operating Margin
-1.06%Return on Assets (TTM)
-3.91%Return on Equity (TTM)
-37.43%Revenue (TTM)
429.09MCNY64.08M · vs all stocks (USD)
Revenue per Share (TTM)
4.29CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-11.30%Gross Profit (TTM)
96.39MCNY14.39M · vs all stocks (USD)
EBITDA (TTM)
-54.30MCNY-8.11M · vs all stocks (USD)
Net Income (TTM)
-284.16MCNY-42.43M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-7.73%Operating Cash Flow (TTM)
10.64MCNY1.59M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
65.96MCNY9.85M · vs all stocks (USD)
5-Year Average Dividend Yield
0.61%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
44.06MCNYFY2025 · Dec 31, 2025Revenue
471.29MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
351.80MCNYFY2025 · Dec 31, 2025Gross Profit
119.48MCNYFY2025 · Dec 31, 2025Operating Income
-84.77MCNY-12.66M · vs all stocks (USD)
Pre-tax Income
-343.39MCNYFY2025 · Dec 31, 2025Income Tax Expense
-7.04MCNYFY2025 · Dec 31, 2025Net Income
-336.35MCNYFY2025 · Dec 31, 2025EBIT
-309.05MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.72MCNYFY2025 · Dec 31, 2025Research & Development
12.15MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
113.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.65MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
34.34MCNYFY2025 · Dec 31, 2025EPS (Basic)
-3.34CNYFY2025 · Dec 31, 2025EPS (Diluted)
-3.34CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
99.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
99.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-336.35MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-326.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-341.98MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
87.82MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-336.35MCNYFY2025 · Dec 31, 2025Other Non-cash Items
35.66MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.05MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.89MCNYFY2025 · Dec 31, 2025Capital Expenditures
-15.35MCNYFY2025 · Dec 31, 2025Net Acquisitions
5.38MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.75MCNYFY2025 · Dec 31, 2025Sale of Investments
924.97KCNYFY2025 · Dec 31, 2025Other Investing Activity
1.49MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-18.30MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
286.05MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-259.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-27.86MCNYFY2025 · Dec 31, 2025Other Financing Charges
31.04MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
29.24MCNYFY2025 · Dec 31, 2025Shares Outstanding
99.88MSharesUpdated Sep 22, 2026Float Shares
47.18MSharesUpdated Sep 22, 2026% Held by Insiders
49.49%vs all stocks
% Held by Institutions
1.00%vs all stocks
Total Cash (MRQ)
62.12MCNY9.28M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6220CNYUpdated Sep 22, 2026Total Debt (MRQ)
696.44MCNY104.00M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.13xCurrent Ratio (MRQ)
0.5900xBook Value per Share (MRQ)
5.21CNYUpdated Sep 22, 2026Total Assets
1.81BCNY270.95M · vs all stocks (USD)
Total Current Assets
589.90MCNYFY2025 · Dec 31, 2025Total Liabilities
1.25BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.22BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
314.93MCNYFY2025 · Dec 31, 2025Total Current Liabilities
930.51MCNYFY2025 · Dec 31, 2025Cash
100.78MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
107.71MCNYFY2025 · Dec 31, 2025Other Short-term Investments
252.20KCNYFY2025 · Dec 31, 2025Accounts Receivable
226.74MCNYFY2025 · Dec 31, 2025Inventory
163.14MCNYFY2025 · Dec 31, 2025Accounts Payable
449.69MCNYFY2025 · Dec 31, 2025Short-term Debt
388.77MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.37MCNYFY2025 · Dec 31, 2025Long-term Debt
246.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
99.88MCNYFY2025 · Dec 31, 2025Retained Earnings
-55.70MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
568.98MCNY84.97M · vs all stocks (USD)
52-Week Low
19.91CNYUpdated Sep 22, 202652-Week High
46.92CNYUpdated Sep 22, 202652-Week Change
68.43%vs all stocks
Beta
0.5820xvs all stocks
50-Day MA
35.98CNYUpdated Sep 22, 2026200-Day MA
31.41CNYUpdated Sep 22, 2026Avg 10-Day Volume
4.58MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.06MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-2.85CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.39: grey zoneSignificant
Altman Z-Score: 1.39
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shattuck Labs Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
476830
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow